Cohance Lifesciences has announced the grant of 80,15,626 stock options to eligible employees under its Employee Stock Option Plan 2023 (ESOP 2023). The grant was approved by the Nomination and Remuneration Committee of the Board of Directors on December 3, 2025. The options will vest as per the terms of the ESOP 2023 scheme, formulated in accordance with SEBI regulations.
ESOP Grant Details
Cohance Lifesciences has approved the allocation of 80,15,626 stock options to its eligible employees under the Employee Stock Option Plan 2023. Each option allows the holder to apply for one equity share of the company.
Vesting and Exercise
Options will vest no earlier than one year and no later than ten years from the grant date. The exercise period for the options extends up to three years from the date of vesting. The Nomination and Remuneration Committee retains the authority to modify the vesting schedule, ensuring alignment with employee interests.
Scheme Compliance
The ESOP 2023 scheme has been formulated in accordance with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.
Source: BSE
